Skip to main content
Premium Trial:

Request an Annual Quote

Aurora, Acacia Settle Dispute, Cross-License Genomic Technologies

Premium

SAN DIEGO, Calif.--Aurora Biosciences and Acacia Biosciences announced that they have agreed to settle an intellectual property dispute by cross-licensing key genomic technologies. Under the agreement, Aurora licensed certain elements of its patented fluorescent protein technology to Acacia, and Acacia licensed elements of its Genome Reporter Matrix technology to Aurora. Aurora also withdrew a patent infringement suit filed against, but not yet served on, Acacia, and Acacia agreed not to challenge the validity or enforceability of the Aurora patents regarding the licensed fluorescent proteins.

Acacia's President and CEO, Bruce Cohen, called the cross-licensing agreement a "useful commercial step for the two companies and a critical milestone for the genomics industry." Cohen added that the agreement "sends a signal to collaborators and investors that biotechnology companies that are active in genomic research and drug discovery can resolve intellectual property differences in a productive manner that does not impair the ability to advance scientific and business objectives."

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.